Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

Recruiting

Early Phase 1

Azeliragon, RT & TMZNeoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

Sponsor:

Washington University School of Medicine

Code:

NCT06831526

Conditions

Glioblastoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Azeliragon

Temozolomide

Radiation therapy

Surgery or LITT

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-21. This information was provided to ClinicalTrials.gov by Washington University School of Medicine on 2025-11-12.